Pivot Park community member Synaffix B.V., a Lonza company, has announced a significant breakthrough with their GlycoConnect™ platform, traditionally used for antibody-drug conjugates (ADCs). Now, their platform shows best-in-class potential in the treatment of neuromuscular diseases, such as Duchenne’s muscular dystrophy (DMD).
In collaboration with Leiden UMC, Synaffix has demonstrated that attaching oligonucleotides to antibodies via the GlycoConnect™ platform led to an unprecedented 90% restoration of dystrophin in a DMD model at a low dose. This groundbreaking data will be presented at key conferences, including the Oligonucleotide Therapeutics Society and the World Muscle Society in October 2024.
This success highlights the versatility of the GlycoConnect™ platform, further positioning Synaffix as a leader in therapeutic innovation.
Read more on their LinkedIn post.